ReviewPharmaceutical research2006
Nanotechnology: intelligent design to treat complex disease.
Review in Pharmaceutical research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed.
- Green Management Strategies forBiology · 2026Review
- Surface decoration of solid lipid nanoparticles with cyclic RGD peptides for precision therapy in high-risk neuroblastoma.Drug delivery and translational research · 2026Article
- A three-pronged strategy with minimalist nattokinase nanocomposite eye drops breaks the vicious cycle in ultraviolet-B-induced cataract.Journal of nanobiotechnology · 2026Article
- Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens.Biomaterials research · 2026Review
- ZnO-Salen NPs Employed as Chemosensor for Detection of AlJournal of fluorescence · 2025Article
- Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Doxorubicin loaded exosomes inhibit cancer-associated fibroblasts growth: in vitro and in vivo study.Cancer cell international · 2025Article
- Nanotechnology-based strategies for vaccine development: accelerating innovation and delivery.Biomaterials translational · 2025Review
- The Role of Glycolipids and their Toxicity in the Context of Nanomaterials and Nanoparticles: A Review of the Literature.Current drug targets · 2025Review
- Liposomal Nanoformulation-encapsulated Paclitaxel for Reducing Chemotherapy Side Effects in Lung Cancer Treatments: Recent Advances and Future Outlooks.Current medicinal chemistry · 2025Review
- Optimized Refolding Buffers Oriented Humoral Immune Responses Versus PfGCS1 Self-Assembled Peptide Nanoparticle.Molecular biotechnology · 2024Article
- Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders.Acta pharmaceutica Sinica. B · 2024Review
- Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease.Nanomaterials (Basel, Switzerland) · 2024Review
- Nanoparticle-Terpene Fusion: A Game-Changer in Combating Primary Amoebic Meningoencephalitis Caused byACS omega · 2024Article
- Development of nanoparticles based on amphiphilic cyclodextrins for the delivery of active substances.International journal of pharmaceutics · 2024Article
- Advances in Nrf2 Signaling Pathway by Targeted Nanostructured-Based Drug Delivery Systems.Biomedicines · 2024Review
- Targeted Treatment Strategies for Mitochondria Dysfunction: Correlation with Neurological Disorders.Current drug targets · 2024Review
- One-Pot Preparation of HCPT@IRMOF-3 Nanoparticles for pH-Responsive Anticancer Drug Delivery.Molecules (Basel, Switzerland) · 2023Article
- Nanotechnology innovations for increasing the productivity of poultry and the prospective of nanobiosensors.Veterinary medicine and science · 2023Review
- Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovaccine Efficacy.International journal of molecular sciences · 2023Review
83 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this expert review is to discuss the impact of nanotechnology in the treatment of the major health threats including cancer, infections, metabolic diseases, autoimmune diseases, and inflammations. Indeed, during the past 30 years, the explosive growth of nanotechnology has burst into challenging innovations in pharmacology, the main input being the ability to perform temporal and spatial site-specific delivery. This has led to some marketed compounds through the last decade. Although the introduction of nanotechnology obviously permitted to step over numerous milestones toward the development of the "magic bullet" proposed a century ago by the immunologist Paul Ehrlich, there are, however, unresolved delivery problems to be still addressed. These scientific and technological locks are discussed along this review together with an analysis of the current situation concerning the industrial development.
Indexed as
Identifiers
16779701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.